Glucagonoma

12 registered clinical trials studyying Glucagonoma.

Status	Trial	Sponsor	Phase
Active Not Recruiting	DOTATOC PET/CT for Imaging NET Patients NCT03583528	British Columbia Cancer Agency	—
Completed	Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors NCT02259725	University of Southern California	Phase 2
Terminated	Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kid NCT02273752	Emory University	Phase 2
Withdrawn	Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors NCT02108782	Academic and Community Cancer Research United	Phase 2
Terminated	Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With S NCT02031536	ECOG-ACRIN Cancer Research Group	Phase 2
Active Not Recruiting	Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors NCT01824875	ECOG-ACRIN Cancer Research Group	Phase 2
Completed	Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors NCT01525082	Shaheen Shagufta	Phase 2
Completed	Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors NCT00131911	National Cancer Institute (NCI)	Phase 2
Completed	Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors NCT00655655	Mayo Clinic	Phase 1
Terminated	Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors NCT00084461	National Cancer Institute (NCI)	Phase 2
Completed	Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors NCT00075439	National Cancer Institute (NCI)	Phase 2
Completed	Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074	National Cancer Institute (NCI)	Phase 1